Reply to "Starting Entyvio"

No, but I did try Entyvio for my UC and was a non-responder.  Dosing for Entyvio is not varied by body weight.  A smaller person has a smaller GI tract than a larger one, but there is no adjustment.  After loading, Entyvio is maintained with an every 8 weeks dose.  Some patients get an every 4 weeks dose.  So there does not seem to be toxicity with higher dosage, either by body size or frequency.  I personally would not be particularly anxious about my missing colon causing an issue.   But, of course, your Doctor would have a better answer. 

You may wish to research on PUBMED .  For example:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532631/

"Data about the effectiveness of biologics, including anti-TNF therapy and anti-integrin strategies, in antibiotic refractory pouchitis or Crohn’s disease-associated pouch complications are sparse. We performed a systematic review of the literature in Medline and Web of Science. All English language publications and meeting abstracts describing patients with pouchitis treated with anti-TNF or anti-integrin therapies were included. We identified a total of 17 papers and 2 abstracts, most of these retrospective case series, including a total of 192 patients treated either with infliximab (IFX; n=140) or adalimumab (ADA; n=52). No reports were found for anti-integrin therapies or other anti-TNF agents such as certolizumab pegol or golimumab. Due to the heterogeneity of the studies, small numbers of patients, differing co-treatments and subjective outcome definitions, the exact efficacy of these biologic therapies cannot be assessed in a combined fashion. Overall IFX appears to have good clinical effectiveness in selected patients achieving up to 80% short and around 50% long-term response, whereas the few data available for ADA are not sufficient to draw valid conclusions. Larger prospectively collected multi-center data with clearly defined inclusion criteria and outcomes are necessary to better define the clinical value of anti-TNF therapy in patients with antibiotic refractory pouchitis or Crohn’s-like complications of the pouch." 

Copyright © 2019 The J-Pouch Group. All rights reserved.
×
×
×
×